Science & Research
The Office of Research and Standards, within the FDA's Office of Generic Drugs (OGD), supports the Science and Research program established under the Generic Drug User Fee Amendments (GDUFA). In collaboration with industry and the public, FDA creates an annual list of regulatory science initiatives on generic drugs. The research studies conducted under these initiatives advance public health by contributing to the development of safe and effective generic drugs. The results provide new tools for FDA to evaluate generic drug equivalence and for industry to efficiently develop new generic products.
Latest Science & Research News
- Advancing Generic Drug Development (AGDD) Virtual Workshop on Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs
Date: August 27, 2026
Register here - Advancing Generic Drug Development (AGDD) Virtual Workshop on Modernizing Bioequivalence Approaches for Topical & Transdermal Products
Date: September 10, 2026
Register here - FDA and the Center for Research on Complex Generics (CRCG) Workshop on Navigating the GLP-1 Generic Drug Pathway
Dates: September 23-24, 2026
Register here